Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 34 entries
Sorted by: Best Match Show Resources per page
HEROES V-V - HEmorRhagic cOmplications in Veno-Venous Extracorporeal life Support - development and internal validation of multivariable prediction model in adult patients.

Artificial organs

Willers A, Swol J, van Kuijk SM, Buscher H, McQuilten Z, Ten Cate H, Rycus PT, McKellar S, Lorusso R, Tonna JE.
PMID: 34904241
Artif Organs. 2021 Dec 13; doi: 10.1111/aor.14148. Epub 2021 Dec 13.

BACKGROUND: During extracorporeal life support (ECLS), bleeding is one of the most frequent complications, associated with high morbidity and increased mortality, despite continuous improvements in devices and patient care. Risk factors for bleeding complications in veno-venous (V-V) ECLS applied...

Cite
Willers A, Swol J, van Kuijk SM, et al. HEROES V-V - HEmorRhagic cOmplications in Veno-Venous Extracorporeal life Support - development and internal validation of multivariable prediction model in adult patients. Artif Organs. 2021;doi: 10.1111/aor.14148.
Willers, A., Swol, J., van Kuijk, S. M., Buscher, H., McQuilten, Z., Ten Cate, H., Rycus, P. T., McKellar, S., Lorusso, R., & Tonna, J. E. (2021). HEROES V-V - HEmorRhagic cOmplications in Veno-Venous Extracorporeal life Support - development and internal validation of multivariable prediction model in adult patients. Artificial organs, . https://doi.org/10.1111/aor.14148
Willers, Anne, et al. "HEROES V-V - HEmorRhagic cOmplications in Veno-Venous Extracorporeal life Support - development and internal validation of multivariable prediction model in adult patients." Artificial organs vol. (2021). doi: https://doi.org/10.1111/aor.14148
Willers A, Swol J, van Kuijk SM, Buscher H, McQuilten Z, Ten Cate H, Rycus PT, McKellar S, Lorusso R, Tonna JE. HEROES V-V - HEmorRhagic cOmplications in Veno-Venous Extracorporeal life Support - development and internal validation of multivariable prediction model in adult patients. Artif Organs. 2021 Dec 13; doi: 10.1111/aor.14148. Epub 2021 Dec 13. PMID: 34904241.
Copy Download .nbib Format: NLM
A point-of-care lateral flow assay for neutralising antibodies against SARS-CoV-2.

EBioMedicine

Fulford TS, Van H, Gherardin NA, Zheng S, Ciula M, Drummer HE, Redmond S, Tan HX, Boo I, Center RJ, Li F, Grimley SL, Wines BD, Nguyen THO, Mordant FL, Ellenberg P, Rowntree LC, Kedzierski L, Cheng AC, Doolan DL, Matthews G, Bond K, Hogarth PM, McQuilten Z, Subbarao K, Kedzierska K, Juno JA, Wheatley AK, Kent SJ, Williamson DA, Purcell DFJ, Anderson DA, Godfrey DI.
PMID: 34871960
EBioMedicine. 2021 Dec 03;74:103729. doi: 10.1016/j.ebiom.2021.103729. Epub 2021 Dec 03.

BACKGROUND: As vaccines against SARS-CoV-2 are now being rolled out, a better understanding of immunity to the virus, whether from infection, or passive or active immunisation, and the durability of this protection is required. This will benefit from the...

Cite
Fulford TS, Van H, Gherardin NA, et al. A point-of-care lateral flow assay for neutralising antibodies against SARS-CoV-2. EBioMedicine. 2021;74:103729doi: 10.1016/j.ebiom.2021.103729.
Fulford, T. S., Van, H., Gherardin, N. A., Zheng, S., Ciula, M., Drummer, H. E., Redmond, S., Tan, H. X., Boo, I., Center, R. J., Li, F., Grimley, S. L., Wines, B. D., Nguyen, T. H. O., Mordant, F. L., Ellenberg, P., Rowntree, L. C., Kedzierski, L., Cheng, A. C., Doolan, D. L., Matthews, G., Bond, K., Hogarth, P. M., McQuilten, Z., Subbarao, K., Kedzierska, K., Juno, J. A., Wheatley, A. K., Kent, S. J., Williamson, D. A., Purcell, D. F. J., Anderson, D. A., & Godfrey, D. I. (2021). A point-of-care lateral flow assay for neutralising antibodies against SARS-CoV-2. EBioMedicine, 74103729. https://doi.org/10.1016/j.ebiom.2021.103729
Fulford, Thomas S, et al. "A point-of-care lateral flow assay for neutralising antibodies against SARS-CoV-2." EBioMedicine vol. 74 (2021): 103729. doi: https://doi.org/10.1016/j.ebiom.2021.103729
Fulford TS, Van H, Gherardin NA, Zheng S, Ciula M, Drummer HE, Redmond S, Tan HX, Boo I, Center RJ, Li F, Grimley SL, Wines BD, Nguyen THO, Mordant FL, Ellenberg P, Rowntree LC, Kedzierski L, Cheng AC, Doolan DL, Matthews G, Bond K, Hogarth PM, McQuilten Z, Subbarao K, Kedzierska K, Juno JA, Wheatley AK, Kent SJ, Williamson DA, Purcell DFJ, Anderson DA, Godfrey DI. A point-of-care lateral flow assay for neutralising antibodies against SARS-CoV-2. EBioMedicine. 2021 Dec 03;74:103729. doi: 10.1016/j.ebiom.2021.103729. Epub 2021 Dec 03. PMID: 34871960; PMCID: PMC8641961.
Copy Download .nbib Format: NLM
Anticoagulation in COVID-19.

Lancet (London, England)

Bradbury CA, McQuilten Z.
PMID: 34921757
Lancet. 2022 Jan 01;399(10319):5-7. doi: 10.1016/S0140-6736(21)02503-4. Epub 2021 Dec 15.

No abstract available.

Cite
Bradbury CA, McQuilten Z. Anticoagulation in COVID-19. Lancet. 2021;399(10319):5-7doi: 10.1016/S0140-6736(21)02503-4.
Bradbury, C. A., & McQuilten, Z. (2022). Anticoagulation in COVID-19. Lancet (London, England), 399(10319), 5-7. https://doi.org/10.1016/S0140-6736(21)02503-4
Bradbury, Charlotte A, and McQuilten, Zoe. "Anticoagulation in COVID-19." Lancet (London, England) vol. 399,10319 (2022): 5-7. doi: https://doi.org/10.1016/S0140-6736(21)02503-4
Bradbury CA, McQuilten Z. Anticoagulation in COVID-19. Lancet. 2022 Jan 01;399(10319):5-7. doi: 10.1016/S0140-6736(21)02503-4. Epub 2021 Dec 15. PMID: 34921757; PMCID: PMC8673870.
Copy Download .nbib Format: NLM
International Forum on Home-Based Blood Transfusion: Responses.

Vox sanguinis

Shaw B, Wood E, McQuilten Z, Callum J, Romon I, Sanroma P, Garcia D, Crispin P, Castilho L, Kutner JM, Yokoyama APH, Bravo A, Sanchez EF, Silva KM, Arora S, Radhakrishnan N, Dua S, Ziman A, Wikman A, Lubenow N, Zingmark LB, Louw V, Loebenberg P, Sidhu D, Redfern T, Nahirniak S, Dunbar N.
PMID: 34697811
Vox Sang. 2021 Oct 25; doi: 10.1111/vox.13199. Epub 2021 Oct 25.

No abstract available.

Cite
Shaw B, Wood E, McQuilten Z, et al. International Forum on Home-Based Blood Transfusion: Responses. Vox Sang. 2021;doi: 10.1111/vox.13199.
Shaw, B., Wood, E., McQuilten, Z., Callum, J., Romon, I., Sanroma, P., Garcia, D., Crispin, P., Castilho, L., Kutner, J. M., Yokoyama, A. P. H., Bravo, A., Sanchez, E. F., Silva, K. M., Arora, S., Radhakrishnan, N., Dua, S., Ziman, A., Wikman, A., Lubenow, N., Zingmark, L. B., Louw, V., Loebenberg, P., Sidhu, D., Redfern, T., Nahirniak, S., & Dunbar, N. (2021). International Forum on Home-Based Blood Transfusion: Responses. Vox sanguinis, . https://doi.org/10.1111/vox.13199
Shaw, Briony, et al. "International Forum on Home-Based Blood Transfusion: Responses." Vox sanguinis vol. (2021). doi: https://doi.org/10.1111/vox.13199
Shaw B, Wood E, McQuilten Z, Callum J, Romon I, Sanroma P, Garcia D, Crispin P, Castilho L, Kutner JM, Yokoyama APH, Bravo A, Sanchez EF, Silva KM, Arora S, Radhakrishnan N, Dua S, Ziman A, Wikman A, Lubenow N, Zingmark LB, Louw V, Loebenberg P, Sidhu D, Redfern T, Nahirniak S, Dunbar N. International Forum on Home-Based Blood Transfusion: Responses. Vox Sang. 2021 Oct 25; doi: 10.1111/vox.13199. Epub 2021 Oct 25. PMID: 34697811.
Copy Download .nbib Format: NLM
A point-of-care lateral flow assay for neutralising antibodies against SARS-CoV-2.

EBioMedicine

Fulford TS, Van H, Gherardin NA, Zheng S, Ciula M, Drummer HE, Redmond S, Tan HX, Boo I, Center RJ, Li F, Grimley SL, Wines BD, Nguyen THO, Mordant FL, Ellenberg P, Rowntree LC, Kedzierski L, Cheng AC, Doolan DL, Matthews G, Bond K, Hogarth PM, McQuilten Z, Subbarao K, Kedzierska K, Juno JA, Wheatley AK, Kent SJ, Williamson DA, Purcell DFJ, Anderson DA, Godfrey DI.
PMID: 34871960
EBioMedicine. 2021 Dec 03;74:103729. doi: 10.1016/j.ebiom.2021.103729. Epub 2021 Dec 03.

BACKGROUND: As vaccines against SARS-CoV-2 are now being rolled out, a better understanding of immunity to the virus, whether from infection, or passive or active immunisation, and the durability of this protection is required. This will benefit from the...

Cite
Fulford TS, Van H, Gherardin NA, et al. A point-of-care lateral flow assay for neutralising antibodies against SARS-CoV-2. EBioMedicine. 2021;74:103729doi: 10.1016/j.ebiom.2021.103729.
Fulford, T. S., Van, H., Gherardin, N. A., Zheng, S., Ciula, M., Drummer, H. E., Redmond, S., Tan, H. X., Boo, I., Center, R. J., Li, F., Grimley, S. L., Wines, B. D., Nguyen, T. H. O., Mordant, F. L., Ellenberg, P., Rowntree, L. C., Kedzierski, L., Cheng, A. C., Doolan, D. L., Matthews, G., Bond, K., Hogarth, P. M., McQuilten, Z., Subbarao, K., Kedzierska, K., Juno, J. A., Wheatley, A. K., Kent, S. J., Williamson, D. A., Purcell, D. F. J., Anderson, D. A., & Godfrey, D. I. (2021). A point-of-care lateral flow assay for neutralising antibodies against SARS-CoV-2. EBioMedicine, 74103729. https://doi.org/10.1016/j.ebiom.2021.103729
Fulford, Thomas S, et al. "A point-of-care lateral flow assay for neutralising antibodies against SARS-CoV-2." EBioMedicine vol. 74 (2021): 103729. doi: https://doi.org/10.1016/j.ebiom.2021.103729
Fulford TS, Van H, Gherardin NA, Zheng S, Ciula M, Drummer HE, Redmond S, Tan HX, Boo I, Center RJ, Li F, Grimley SL, Wines BD, Nguyen THO, Mordant FL, Ellenberg P, Rowntree LC, Kedzierski L, Cheng AC, Doolan DL, Matthews G, Bond K, Hogarth PM, McQuilten Z, Subbarao K, Kedzierska K, Juno JA, Wheatley AK, Kent SJ, Williamson DA, Purcell DFJ, Anderson DA, Godfrey DI. A point-of-care lateral flow assay for neutralising antibodies against SARS-CoV-2. EBioMedicine. 2021 Dec 03;74:103729. doi: 10.1016/j.ebiom.2021.103729. Epub 2021 Dec 03. PMID: 34871960; PMCID: PMC8641961.
Copy Download .nbib Format: NLM
A point-of-care lateral flow assay for neutralising antibodies against SARS-CoV-2.

EBioMedicine

Fulford TS, Van H, Gherardin NA, Zheng S, Ciula M, Drummer HE, Redmond S, Tan HX, Boo I, Center RJ, Li F, Grimley SL, Wines BD, Nguyen THO, Mordant FL, Ellenberg P, Rowntree LC, Kedzierski L, Cheng AC, Doolan DL, Matthews G, Bond K, Hogarth PM, McQuilten Z, Subbarao K, Kedzierska K, Juno JA, Wheatley AK, Kent SJ, Williamson DA, Purcell DFJ, Anderson DA, Godfrey DI.
PMID: 34871960
EBioMedicine. 2021 Dec 03;74:103729. doi: 10.1016/j.ebiom.2021.103729. Epub 2021 Dec 03.

BACKGROUND: As vaccines against SARS-CoV-2 are now being rolled out, a better understanding of immunity to the virus, whether from infection, or passive or active immunisation, and the durability of this protection is required. This will benefit from the...

Cite
Fulford TS, Van H, Gherardin NA, et al. A point-of-care lateral flow assay for neutralising antibodies against SARS-CoV-2. EBioMedicine. 2021;74:103729doi: 10.1016/j.ebiom.2021.103729.
Fulford, T. S., Van, H., Gherardin, N. A., Zheng, S., Ciula, M., Drummer, H. E., Redmond, S., Tan, H. X., Boo, I., Center, R. J., Li, F., Grimley, S. L., Wines, B. D., Nguyen, T. H. O., Mordant, F. L., Ellenberg, P., Rowntree, L. C., Kedzierski, L., Cheng, A. C., Doolan, D. L., Matthews, G., Bond, K., Hogarth, P. M., McQuilten, Z., Subbarao, K., Kedzierska, K., Juno, J. A., Wheatley, A. K., Kent, S. J., Williamson, D. A., Purcell, D. F. J., Anderson, D. A., & Godfrey, D. I. (2021). A point-of-care lateral flow assay for neutralising antibodies against SARS-CoV-2. EBioMedicine, 74103729. https://doi.org/10.1016/j.ebiom.2021.103729
Fulford, Thomas S, et al. "A point-of-care lateral flow assay for neutralising antibodies against SARS-CoV-2." EBioMedicine vol. 74 (2021): 103729. doi: https://doi.org/10.1016/j.ebiom.2021.103729
Fulford TS, Van H, Gherardin NA, Zheng S, Ciula M, Drummer HE, Redmond S, Tan HX, Boo I, Center RJ, Li F, Grimley SL, Wines BD, Nguyen THO, Mordant FL, Ellenberg P, Rowntree LC, Kedzierski L, Cheng AC, Doolan DL, Matthews G, Bond K, Hogarth PM, McQuilten Z, Subbarao K, Kedzierska K, Juno JA, Wheatley AK, Kent SJ, Williamson DA, Purcell DFJ, Anderson DA, Godfrey DI. A point-of-care lateral flow assay for neutralising antibodies against SARS-CoV-2. EBioMedicine. 2021 Dec 03;74:103729. doi: 10.1016/j.ebiom.2021.103729. Epub 2021 Dec 03. PMID: 34871960; PMCID: PMC8641961.
Copy Download .nbib Format: NLM
Epidemiology of Massive Transfusion - A Common Intervention in Need of a Definition.

Transfusion medicine reviews

McQuilten ZK, Flint AW, Green L, Sanderson B, Winearls J, Wood EM.
PMID: 34690031
Transfus Med Rev. 2021 Oct;35(4):73-79. doi: 10.1016/j.tmrv.2021.08.006. Epub 2021 Oct 21.

While massive transfusion (MT) recipients account for a small proportion of all transfused patients, they account for approximately 10% of blood products issued. Furthermore, MT events pose organizational and logistical challenges for health care providers, laboratory and transfusion services....

Cite
McQuilten ZK, Flint AW, Green L, et al. Epidemiology of Massive Transfusion - A Common Intervention in Need of a Definition. Transfus Med Rev. 2021;35(4):73-79doi: 10.1016/j.tmrv.2021.08.006.
McQuilten, Z. K., Flint, A. W., Green, L., Sanderson, B., Winearls, J., & Wood, E. M. (2021). Epidemiology of Massive Transfusion - A Common Intervention in Need of a Definition. Transfusion medicine reviews, 35(4), 73-79. https://doi.org/10.1016/j.tmrv.2021.08.006
McQuilten, Zoe K, et al. "Epidemiology of Massive Transfusion - A Common Intervention in Need of a Definition." Transfusion medicine reviews vol. 35,4 (2021): 73-79. doi: https://doi.org/10.1016/j.tmrv.2021.08.006
McQuilten ZK, Flint AW, Green L, Sanderson B, Winearls J, Wood EM. Epidemiology of Massive Transfusion - A Common Intervention in Need of a Definition. Transfus Med Rev. 2021 Oct;35(4):73-79. doi: 10.1016/j.tmrv.2021.08.006. Epub 2021 Oct 21. PMID: 34690031.
Copy Download .nbib Format: NLM
Vox Sanguinis International Forum on provision of granulocytes for transfusion and their clinical use: summary.

Vox sanguinis

Morton S, Stanworth S, Lozano M, Harrison SJ, Hong FS, Dennington P, McQuilten Z, Worel N, Compernolle V, Kutner JM, Yokoyama APH, Nahirniak S, Germain M, Hume H, Robitaille N, Wilson A, Tinmouth A, Massey E, Boulat C, Woimant G, Tiberghien P, Schulze TJ, Bux J, Pierelli L, Ballester C, Netelenbos T, West KA, Conry-Cantilena C, Eder A, Haley NR, Yazer M, Triulzi D.
PMID: 28905391
Vox Sang. 2017 Oct;112(7):680-683. doi: 10.1111/vox.12522. Epub 2017 Sep 14.

No abstract available.

Cite
Morton S, Stanworth S, Lozano M, et al. Vox Sanguinis International Forum on provision of granulocytes for transfusion and their clinical use: summary. Vox Sang. 2017;112(7):680-683doi: 10.1111/vox.12522.
Morton, S., Stanworth, S., Lozano, M., Harrison, S. J., Hong, F. S., Dennington, P., McQuilten, Z., Worel, N., Compernolle, V., Kutner, J. M., Yokoyama, A. P. H., Nahirniak, S., Germain, M., Hume, H., Robitaille, N., Wilson, A., Tinmouth, A., Massey, E., Boulat, C., Woimant, G., Tiberghien, P., Schulze, T. J., Bux, J., Pierelli, L., Ballester, C., Netelenbos, T., West, K. A., Conry-Cantilena, C., Eder, A., Haley, N. R., Yazer, M., & Triulzi, D. (2017). Vox Sanguinis International Forum on provision of granulocytes for transfusion and their clinical use: summary. Vox sanguinis, 112(7), 680-683. https://doi.org/10.1111/vox.12522
Morton, S, et al. "Vox Sanguinis International Forum on provision of granulocytes for transfusion and their clinical use: summary." Vox sanguinis vol. 112,7 (2017): 680-683. doi: https://doi.org/10.1111/vox.12522
Morton S, Stanworth S, Lozano M, Harrison SJ, Hong FS, Dennington P, McQuilten Z, Worel N, Compernolle V, Kutner JM, Yokoyama APH, Nahirniak S, Germain M, Hume H, Robitaille N, Wilson A, Tinmouth A, Massey E, Boulat C, Woimant G, Tiberghien P, Schulze TJ, Bux J, Pierelli L, Ballester C, Netelenbos T, West KA, Conry-Cantilena C, Eder A, Haley NR, Yazer M, Triulzi D. Vox Sanguinis International Forum on provision of granulocytes for transfusion and their clinical use: summary. Vox Sang. 2017 Oct;112(7):680-683. doi: 10.1111/vox.12522. Epub 2017 Sep 14. PMID: 28905391.
Copy Download .nbib Format: NLM
Hemoglobin is a key determinant of quality of life before and during azacitidine-based therapy for myelodysplasia and low blast count acute myeloid leukemia.

Leukemia & lymphoma

McQuilten ZK, Busija L, Seymour JF, Stanworth S, Wood EM, Kenealy M, Weinkove R.
PMID: 34915809
Leuk Lymphoma. 2021 Dec 17;1-8. doi: 10.1080/10428194.2021.2012664. Epub 2021 Dec 17.

Myelodysplastic syndromes (MDS) have a major impact on quality of life (QoL). We performed a

Cite
McQuilten ZK, Busija L, Seymour JF, et al. Hemoglobin is a key determinant of quality of life before and during azacitidine-based therapy for myelodysplasia and low blast count acute myeloid leukemia. Leuk Lymphoma. 2021;1-8doi: 10.1080/10428194.2021.2012664.
McQuilten, Z. K., Busija, L., Seymour, J. F., Stanworth, S., Wood, E. M., Kenealy, M., Weinkove, R. (2021). Hemoglobin is a key determinant of quality of life before and during azacitidine-based therapy for myelodysplasia and low blast count acute myeloid leukemia. Leukemia & lymphoma, 1-8. https://doi.org/10.1080/10428194.2021.2012664
McQuilten, Zoe K, et al. "Hemoglobin is a key determinant of quality of life before and during azacitidine-based therapy for myelodysplasia and low blast count acute myeloid leukemia." Leukemia & lymphoma vol. (2021): 1-8. doi: https://doi.org/10.1080/10428194.2021.2012664
McQuilten ZK, Busija L, Seymour JF, Stanworth S, Wood EM, Kenealy M, Weinkove R. Hemoglobin is a key determinant of quality of life before and during azacitidine-based therapy for myelodysplasia and low blast count acute myeloid leukemia. Leuk Lymphoma. 2021 Dec 17;1-8. doi: 10.1080/10428194.2021.2012664. Epub 2021 Dec 17. PMID: 34915809.
Copy Download .nbib Format: NLM
A point-of-care lateral flow assay for neutralising antibodies against SARS-CoV-2.

EBioMedicine

Fulford TS, Van H, Gherardin NA, Zheng S, Ciula M, Drummer HE, Redmond S, Tan HX, Boo I, Center RJ, Li F, Grimley SL, Wines BD, Nguyen THO, Mordant FL, Ellenberg P, Rowntree LC, Kedzierski L, Cheng AC, Doolan DL, Matthews G, Bond K, Hogarth PM, McQuilten Z, Subbarao K, Kedzierska K, Juno JA, Wheatley AK, Kent SJ, Williamson DA, Purcell DFJ, Anderson DA, Godfrey DI.
PMID: 34871960
EBioMedicine. 2021 Dec 03;74:103729. doi: 10.1016/j.ebiom.2021.103729. Epub 2021 Dec 03.

BACKGROUND: As vaccines against SARS-CoV-2 are now being rolled out, a better understanding of immunity to the virus, whether from infection, or passive or active immunisation, and the durability of this protection is required. This will benefit from the...

Cite
Fulford TS, Van H, Gherardin NA, et al. A point-of-care lateral flow assay for neutralising antibodies against SARS-CoV-2. EBioMedicine. 2021;74:103729doi: 10.1016/j.ebiom.2021.103729.
Fulford, T. S., Van, H., Gherardin, N. A., Zheng, S., Ciula, M., Drummer, H. E., Redmond, S., Tan, H. X., Boo, I., Center, R. J., Li, F., Grimley, S. L., Wines, B. D., Nguyen, T. H. O., Mordant, F. L., Ellenberg, P., Rowntree, L. C., Kedzierski, L., Cheng, A. C., Doolan, D. L., Matthews, G., Bond, K., Hogarth, P. M., McQuilten, Z., Subbarao, K., Kedzierska, K., Juno, J. A., Wheatley, A. K., Kent, S. J., Williamson, D. A., Purcell, D. F. J., Anderson, D. A., & Godfrey, D. I. (2021). A point-of-care lateral flow assay for neutralising antibodies against SARS-CoV-2. EBioMedicine, 74103729. https://doi.org/10.1016/j.ebiom.2021.103729
Fulford, Thomas S, et al. "A point-of-care lateral flow assay for neutralising antibodies against SARS-CoV-2." EBioMedicine vol. 74 (2021): 103729. doi: https://doi.org/10.1016/j.ebiom.2021.103729
Fulford TS, Van H, Gherardin NA, Zheng S, Ciula M, Drummer HE, Redmond S, Tan HX, Boo I, Center RJ, Li F, Grimley SL, Wines BD, Nguyen THO, Mordant FL, Ellenberg P, Rowntree LC, Kedzierski L, Cheng AC, Doolan DL, Matthews G, Bond K, Hogarth PM, McQuilten Z, Subbarao K, Kedzierska K, Juno JA, Wheatley AK, Kent SJ, Williamson DA, Purcell DFJ, Anderson DA, Godfrey DI. A point-of-care lateral flow assay for neutralising antibodies against SARS-CoV-2. EBioMedicine. 2021 Dec 03;74:103729. doi: 10.1016/j.ebiom.2021.103729. Epub 2021 Dec 03. PMID: 34871960; PMCID: PMC8641961.
Copy Download .nbib Format: NLM
TLR2-mediated activation of innate responses in the upper airways confers antiviral protection of the lungs.

JCI insight

Deliyannis G, Wong CY, McQuilten HA, Bachem A, Clarke M, Jia X, Horrocks K, Zeng W, Girkin J, Scott NE, Londrigan SL, Reading PC, Bartlett NW, Kedzierska K, Brown LE, Mercuri F, Demaison C, Jackson DC, Chua BY.
PMID: 33561017
JCI Insight. 2021 Mar 08;6(5). doi: 10.1172/jci.insight.140267.

The impact of respiratory virus infections on global health is felt not just during a pandemic, but endemic seasonal infections pose an equal and ongoing risk of severe disease. Moreover, vaccines and antiviral drugs are not always effective or...

Cite
Deliyannis G, Wong CY, McQuilten HA, et al. TLR2-mediated activation of innate responses in the upper airways confers antiviral protection of the lungs. JCI Insight. 2021;6(5)doi: 10.1172/jci.insight.140267.
Deliyannis, G., Wong, C. Y., McQuilten, H. A., Bachem, A., Clarke, M., Jia, X., Horrocks, K., Zeng, W., Girkin, J., Scott, N. E., Londrigan, S. L., Reading, P. C., Bartlett, N. W., Kedzierska, K., Brown, L. E., Mercuri, F., Demaison, C., Jackson, D. C., & Chua, B. Y. (2021). TLR2-mediated activation of innate responses in the upper airways confers antiviral protection of the lungs. JCI insight, 6(5), . https://doi.org/10.1172/jci.insight.140267
Deliyannis, Georgia, et al. "TLR2-mediated activation of innate responses in the upper airways confers antiviral protection of the lungs." JCI insight vol. 6,5 (2021). doi: https://doi.org/10.1172/jci.insight.140267
Deliyannis G, Wong CY, McQuilten HA, Bachem A, Clarke M, Jia X, Horrocks K, Zeng W, Girkin J, Scott NE, Londrigan SL, Reading PC, Bartlett NW, Kedzierska K, Brown LE, Mercuri F, Demaison C, Jackson DC, Chua BY. TLR2-mediated activation of innate responses in the upper airways confers antiviral protection of the lungs. JCI Insight. 2021 Mar 08;6(5). doi: 10.1172/jci.insight.140267. PMID: 33561017; PMCID: PMC8021123.
Copy Download .nbib Format: NLM
Clinical illness with viable severe acute respiratory coronavirus virus 2 (SARS-CoV-2) virus presenting 72 days after infection in an immunocompromised patient.

Infection control and hospital epidemiology

Hughes CM, Gregory GP, Pierce AB, Druce JD, Catton M, Chong B, Sherry NL, Graham M, Chen M, Salvaris R, Eise N, Lee JYH, McQuilten Z, Crouch S, Looker C, Korman TM, Stuart RL.
PMID: 33736721
Infect Control Hosp Epidemiol. 2021 Mar 19;1-3. doi: 10.1017/ice.2021.120. Epub 2021 Mar 19.

No abstract available.

Cite
Hughes CM, Gregory GP, Pierce AB, et al. Clinical illness with viable severe acute respiratory coronavirus virus 2 (SARS-CoV-2) virus presenting 72 days after infection in an immunocompromised patient. Infect Control Hosp Epidemiol. 2021;1-3doi: 10.1017/ice.2021.120.
Hughes, C. M., Gregory, G. P., Pierce, A. B., Druce, J. D., Catton, M., Chong, B., Sherry, N. L., Graham, M., Chen, M., Salvaris, R., Eise, N., Lee, J. Y. H., McQuilten, Z., Crouch, S., Looker, C., Korman, T. M., & Stuart, R. L. (2021). Clinical illness with viable severe acute respiratory coronavirus virus 2 (SARS-CoV-2) virus presenting 72 days after infection in an immunocompromised patient. Infection control and hospital epidemiology, 1-3. https://doi.org/10.1017/ice.2021.120
Hughes, Carly M, et al. "Clinical illness with viable severe acute respiratory coronavirus virus 2 (SARS-CoV-2) virus presenting 72 days after infection in an immunocompromised patient." Infection control and hospital epidemiology vol. (2021): 1-3. doi: https://doi.org/10.1017/ice.2021.120
Hughes CM, Gregory GP, Pierce AB, Druce JD, Catton M, Chong B, Sherry NL, Graham M, Chen M, Salvaris R, Eise N, Lee JYH, McQuilten Z, Crouch S, Looker C, Korman TM, Stuart RL. Clinical illness with viable severe acute respiratory coronavirus virus 2 (SARS-CoV-2) virus presenting 72 days after infection in an immunocompromised patient. Infect Control Hosp Epidemiol. 2021 Mar 19;1-3. doi: 10.1017/ice.2021.120. Epub 2021 Mar 19. PMID: 33736721; PMCID: PMC8220010.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 34 entries